PBT up 25.7% on ARC scale, full-year dividend reset to 8.0c

Aged Medical Care (ARC) did almost all of the heavy lifting: ARC revenue grew to $14.9m and lifted to 66.3% of group revenue from 61.6%, while the Community GP business rose only 3.2% to $7.6m. Effective tax rate was stable at 29.4% versus 29.2%, so the operating read is genuinely PBT-led rather than tax-flattered.

Two non-operating signals stand out. Cash conversion (OCF/EBITDA) eased to 70.1% from 79.1% as operating cash flow grew just 8.9% against 22.9% EBITDA growth. And the declared full-year dividend stepped down to 8.0c per share from 14.71c, taking the NPAT payout ratio from 62.8% to 28.2% — a clear policy reset rather than a marginal adjustment.

Aged-care revenue grew while segment margin moved only modestly (to 24.4% from 24.0%), and the Executive Chairman's letter explicitly frames a deliberate trade of short-term margin for workforce retention, capability and digital build. This matters because group margin durability now depends on a segment being actively reinvested in, not optimised.

Cash conversion deteriorated meaningfully even though absolute cash flow rose. OCF grew $0.3m on $1.1m of EBITDA growth, implying around $0.9m of incremental earnings did not convert. With capex still negligible at 0.4% of revenue, FCF/NPAT remained strong at 139.8%, but the gap between EBITDA growth and OCF growth is the type of slippage that compounds if working capital does not unwind.

The dividend reset is the most consequential capital-allocation signal in the release. Reducing the full-year distribution to 8.0c from 14.71c while NPAT grew is a deliberate retention of cash for the ARC build-out and digital enablement program described in the chair's letter. It also lines up with payout against pre-lease FCF dropping to 20.2%, leaving substantial headroom for either further investment or future restoration.

HY26 produced 47.4% of full-year revenue, 48.0% of EBITDA and 50.1% of NPAT, suggesting a mildly second-half-weighted year on top-line but a roughly even profit cadence — which means the implied H2 NPAT of about $1.4m was steady rather than accelerating.

The chair's commentary frames ongoing investment in ARC and digital enablement as a multi-year theme. Without a stated revenue target or forward order-book equivalent, the release supports a thesis of continued ARC-led growth and reinvestment, but does not anchor the rate.

PBT (+25.7%) running ahead of NPAT (+21.7%) reflects a 4.0pp gap that traces to minority interest on the consolidated ARC operation rather than tax distortion, with the effective tax rate essentially flat at 29.4%. Net debt remains negative (net cash $1.8m), gross borrowings ticked down to $1.1m, and equity rose 38.8% to $5.5m — all genuine balance-sheet strengthening.

The softer points are the cash-conversion slippage and the implicit margin commentary in ARC. OCF/EBITDA at 70.1% is not weak in absolute terms but the 9.0pp year-on-year decline indicates that a portion of FY26 earnings sits in working capital rather than bank. Combined with the chair's explicit statement that ARC margins were compressed by workforce-cost choices, the read is that the result is real but is being earned in a phase where management is prioritising scale and care quality over peak conversion.

This briefing cannot assess unit-level operating metrics such as enrolled patient growth, ARC contract pipeline, or organic versus acquisition contribution within ARC, because the release does not disclose them on a comparable basis.